ArticleCancers2023

The First-In-Class Anti-AXL×CD3ε Pronectin™-Based Bispecific T-Cell Engager Is Active in Preclinical Models of Human Soft Tissue and Bone Sarcomas.

Nicoletta Polerà et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.